{
    "nct_id": "NCT03955042",
    "official_title": "Pilot Study of Pemetrexed for the Treatment of Chordoma",
    "inclusion_criteria": "1. Participant has the ability to understand and the willingness to provide a signed and dated informed consent form.\n2. Participant has the willingness to comply with all study procedures and availability for the duration of the study.\n3. Participant has a diagnosis of chordoma.\n4. Participant is male or female, 18 years of age or older.\n5. Participant has a Karnofsky Performance Status of 50% or greater.\n6. Participant has adequate organ function:\n\n   1. ANC at least 1.5 x 10^9/L or higher\n   2. Platelets at least 100 x 10^9/L or higher\n   3. Hemoglobin at least 8 g/dL or higher.\n   4. Total bilirubin 1.5 x upper limit of normal (ULN) or lower.\n   5. ALT and AST 3 x ULN or lower.\n   6. Serum creatinine 1.5 x ULN or lower.\n7. Participant has the ability to interrupt non-steroidal anti-inflammatory drugs (NSAIDS) 2 days before (5 days for long-acting NSAIDs), the day of, and 2 days following administration of Pemetrexed.\n8. Participant has the ability to take folic acid, Vitamin B12, and dexamethasone according to protocol.\n9. Participant has recovered from any previous therapy-related toxicity to CTCAE Grade 1 or to their clinical baseline at study entry.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "1. Participant is less than 28 days from any investigational agent.\n2. Participant has third space fluid which cannot be controlled by drainage.\n3. Participant has a severe or uncontrolled medical disorder that would, in the investigator's opinion, impair ability to receive study intervention, including, but not limited to:\n\n   1. Uncontrolled diabetes;\n   2. Renal disease that requires dialysis;\n   3. Pulmonary disorder requiring supplemental oxygen to keep saturation >95% and the situation is not expected to resolve within 2 weeks;\n   4. Severe dyspnea at rest or requiring oxygen therapy;\n   5. Interstitial lung disease;\n   6. History of major surgical resection involving the stomach or small bowel;\n   7. Preexisting Crohn's disease;\n   8. Ulcerative colitis;\n   9. Uncontrolled vasculitis and/or disease with known vasculitis;\n   10. Preexisting chronic condition resulting in baseline Grade 2 or higher diarrhea;\n   11. Psychiatric illness/social situations that would limit compliance with study requirements.\n4. Participant has an active bacterial infection requiring intravenous [IV] antibiotics at time of initiating study treatment, fungal infection, or detectable viral infection (such as known human immunodeficiency virus positivity or with known active hepatitis B or C).\n5. Participant has a personal history or presence of any of the following cardiovascular conditions:\n\n   1. Syncope of cardiovascular etiology;\n   2. Ventricular arrhythmia of pathological origin (including, but not limited to, ventricular tachycardia and ventricular fibrillation);\n   3. Myocardial infraction within 6 months of investigational product administration;\n   4. Unstable angina;\n   5. Sudden cardiac arrest;\n   6. Congestive heart failure (NYHA classification â‰¥ 3).\n6. Participant is a female of childbearing potential who is pregnant or nursing.",
    "miscellaneous_criteria": ""
}